Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

BeiGene, Ltd. - American Depositary Shares (NQ: ONC )

254.57 +4.73 (+1.89%)
Official Closing Price Updated: 4:15 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BeiGene, Ltd. - American Depositary Shares

Earnings Scheduled For March 7, 2025
Via Benzinga
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1-positive patients. 
Via Benzinga
Exposures Product Safety
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
From BeiGene, Ltd.
Via Business Wire
Earnings Scheduled For February 27, 2025
Via Benzinga
BeiGene to Present at Upcoming Investor Conferences
From BeiGene
Via Business Wire
Alibaba, Super Micro Computer And XPeng Are Among Top 10 Large Cap Gainers Last Week (Feb 17-Feb 21): Are The Others In Your Portfolio?
Top performing large-cap stocks in the last week: Unity, Super Micro Computer, Alibaba, FTAI Aviation, STMicroelectronics, XPeng, Analog Devices, BeiGene, Tencent Music, Microchip Technology. 
Via Benzinga
BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27
From BeiGene, Ltd.
Via Business Wire
ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism
The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for certain patients with advanced or metastatic non-small cell lung cancer 
Via Stocktwits
Leap Therapeutics Halts Sirexatamab Combo Therapy For Gastric Cancer ON Unclear Positive Signal, Stock Crashes
Leap Therapeutics' Phase 2 data shows sirexatamab improves ORR in colorectal cancer. Gastric cancer studies end due to lack of PFS benefit. 
Via Benzinga
MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
These 11 large-cap stocks saw significant growth last week, with notable news from companies such as Johnson & Johnson, MicroStrategy, and United Rentals. 
Via Benzinga
BeiGene Stock Meets 80-Plus RS Rating Benchmark
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.